Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
ArriVent BioPharma, Inc. (AVBP) had Normalized Income after Taxes of $-43.32M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-43.32M |
|
-- |
|
-- |
|
$46.11M |
|
$-46.11M |
|
$2.79M |
|
$-43.32M |
|
$-43.32M |
|
$-43.32M |
|
$-43.32M |
|
$-43.32M |
|
|
Normalized Income after Taxes |
$-43.32M |
$-46.11M |
|
$-46.67M |
|
45.07M |
|
45.07M |
|
$-0.96 |
|
$-0.96 |
|
| Balance Sheet Financials | |
$348.70M |
|
-- |
|
$0.59M |
|
$349.30M |
|
$25.00M |
|
-- |
|
$0.32M |
|
$25.32M |
|
$323.98M |
|
$323.98M |
|
$323.98M |
|
45.31M |
|
| Cash Flow Statement Financials | |
$-41.89M |
|
$3.58M |
|
$54.87M |
|
$45.54M |
|
$62.10M |
|
$16.56M |
|
$5.49M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.95 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-41.89M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.37% |
|
-13.37% |
|
-12.40% |
|
-13.37% |
|
$7.15 |
|
$-0.93 |
|
$-0.93 |
|